Peanut Sensitivity vs. Allergy: Natural History, Outgrowing Potential, and Management

"Peanut sensitivity" is a lay term often conflating distinct entities. Precision matters: IgE-mediated peanut allergy (immune-mediated, anaphylaxis risk) differs from non-IgE-mediated reactions (e.g., FPIES, contact urticaria) and oral allergy syndrome (pollen-food syndrome) (birch pollen cross-reactivity, usually mild oropharyngeal symptoms).

Natural History of IgE-Mediated Peanut Allergy

• Prevalence: ~2% children, ~1–2% adults (increasing).
• Persistence: ~80% persist into adulthood; ~20% outgrow by adolescence.
• Predictors of persistence: higher peanut sIgE, larger SPT wheal, comorbid asthma/eczema, multiple food allergies, late onset.
• Predictors of resolution: low sIgE, small SPT, isolated peanut allergy, early onset, favorable component-resolved diagnostics (Ara h 2 vs Ara h 8).

Component-Resolved Diagnostics (CRD)

• Ara h 1, 2, 3, 6: Storage proteins; stable to heat/digestion; associated with systemic anaphylaxis risk.
• Ara h 8 (PR-10): Bet v 1 homolog; cross-reactivity with birch pollen; usually mild OAS.
• Ara h 9 (LTP): Lipid transfer protein; stable; associated with systemic reactions in Mediterranean populations.

CRD refines risk stratification beyond extract-based testing.

Prevention: Early Introduction

LEAP trial: Early peanut introduction (4–11 months) in high-risk infants reduced allergy by 81%. NIAID guidelines: assess risk, test if high-risk, introduce early at home or supervised.

Management

• Strict Avoidance + Two Epinephrine Auto-Injectors + Action Plan + Medical ID.
• Oral Immunotherapy (OIT): Palforzia (FDA-approved, 4–17 yrs) or real-world peanut flour protocols. Desensitization, not cure; daily maintenance required; anaphylaxis risk during up-dosing.
• Epicutaneous Immunotherapy (EPIT): Viaskin Peanut patch (under FDA review).
• Biologics as Adjuncts: Omalizumab + OIT accelerates up-dosing, reduces reactions (OUtMATCH trial).

Monitoring for Resolution

• Annual allergist follow-up: history, SPT, sIgE (extract + components).
• Declining sIgE/SPT + clinical tolerance → consider supervised oral food challenge (gold standard).
• Home introduction never—only in equipped facility.

Non-IgE "Sensitivities"

• FPIES (Food Protein-Induced Enterocolitis Syndrome): Delayed (1–4h) profuse vomiting, lethargy, hypotension; peanut rare trigger (cow's milk, soy, rice, oats common). Diagnosed by history; managed by avoidance; often outgrown by 3–5 yrs.
• Pollen-Food Syndrome (OAS): Birch-allergic patients react to raw peanut (Ara h 8); roasted peanut often tolerated. Not anaphylaxis-prone.

Accurate diagnosis is the foundation. "Sensitivity" is not a diagnosis—seek board-certified allergist evaluation for proper classification and management.